The efficacy and safety of anti-PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.

被引：0
|
作者：
Chen, Jiaying
Ji, Qinghai
Wang, Yu
Huang, Naisi
Hu, Jiaqian
Wei, Wenjun
Huang, Caiping
Shen, Qiang
Li, Duanshu
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Head & Neck Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6084
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
    Wang, J.
    Zhang, Z.
    Zhang, F.
    Song, Q.
    Zhang, L.
    Liu, Z.
    Ma, J.
    Yan, X.
    Wang, L.
    Tao, H.
    Zhang, S.
    Li, X.
    Zhi, X.
    Hu, Y.
    Jiao, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [12] Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study.
    Zhang, Geng
    Fu, Qiang
    Zhang, Fuxun
    Yang, Fan
    Hou, Haozhong
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [13] A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.
    Shen, Jie
    Kong, Weiwei
    Zhu, Sihui
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [14] A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
    Zhou, Mingzhen
    Jin, Yuncheng
    Zhu, Sihui
    Xu, Chen
    Li, Lin
    Liu, Baorui
    Shen, Jie
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (01)
  • [15] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
  • [16] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [17] Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
    Gao, Qinglei
    Wang, Jing
    Xu, Qin
    Tang, Ying
    Zhang, Jieqing
    Chang, Baoping
    Xia, Bairong
    Duan, Wei
    Wang, Danbo
    Zhu, Lijing
    An, Ruifang
    Zhang, Guonan
    Tang, Yaling
    Huang, Jianli
    Zhang, Xiang
    Qiu, Hui
    Ji, Wenting
    Li, Li
    Zhu, Jianqing
    Ma, Ding
    CANCER RESEARCH, 2023, 83 (08)
  • [18] First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+locally advanced or metastatic urothelial carcinoma (UC) in Asian patients
    Ye, D.
    Liu, J.
    Zhou, A.
    Zou, Q.
    Li, H.
    Fu, C.
    Hu, H.
    Huang, J.
    Zhu, S.
    Jin, J.
    Ma, L.
    Guo, J.
    Xiao, J.
    Park, S. H.
    Zhang, D.
    Qiu, X.
    Bao, Y.
    Zhang, L.
    Shen, W.
    Feng, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 367 - 367
  • [19] Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
    Shi, Shuling
    Li, Bingyan
    Zhou, Pengcheng
    Chen, Linhui
    Li, Huizhen
    Wang, Yingyi
    Deng, Xiaoyu
    Dang, Qianqian
    Wu, Jingjing
    Zha, Boya
    Li, Peihong
    Zheng, Yingjuan
    Yang, Daoke
    CANCER MEDICINE, 2024, 13 (14):
  • [20] Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
    Li Yang
    Xian-Zhe Dong
    Xiao-Xuan Xing
    Xiao-Hui Cui
    Lin Li
    Lan Zhang
    World Journal of Gastrointestinal Oncology, 2020, (11) : 1346 - 1358
12345